PMID- 23388885
OWN - NLM
STAT- MEDLINE
DCOM- 20140109
LR  - 20210402
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in 
      patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic 
      syndrome and the effect of statin therapy.
PG  - 550-8
LID - 10.1038/hr.2012.214 [doi]
AB  - The objective of this study was to determine the relationship of HTN (HTN) and 
      the inflammatory markers C-reactive protein (CRP), monocyte chemoattractant 
      protein-1 (MCP-1), amyloid alpha (AA) and interleukin-18 (IL-18) in persons with 
      HTN, considering concomitant diabetes mellitus (DM) or metabolic syndrome (MS). 
      This was a multicenter twelve-week, single-step titration, open-label study of 
      individuals with dyslipidemia, assigned according to their initial risk 
      assessment, to atorvastatin starting doses of 10, 20, 40 or 80 mg. In subjects 
      with HTN (N=677) versus no HTN (N=581), there were significantly (P<0.02) higher 
      levels of CRP, IL-18, MCP-1 and AA but not for IL-18 when combined with DM or MS, 
      and AA or CRP when combined with MS. Systolic blood pressure significantly 
      (P<0.02) correlated with CRP, MCP-1 and AA but not IL-18. The greatest increase 
      in CRP was with HTN plus DM. Statin therapy produced significant dose-dependent 
      reductions in CRP but not with similar changes in other inflammatory markers. In 
      summary, these data suggest a complex relationship between inflammation and HTN 
      with dyslipidemia. Although HTN is associated with an increase in these 
      inflammatory markers, the associated conditions DM or MS lead to different 
      patterns of increases-MCP-1 being the most consistently increased with HTN, the 
      greatest CRP increase was with HTN and DM, and no relationship was found with 
      IL-18 and HTN in the presence of DM or MS. In addition, there are different 
      responses to statins depending on the nature of the inflammatory marker.
FAU - Rabkin, Simon W
AU  - Rabkin SW
AD  - University of British Columbia, Vancouver, British Columbia, Canada. 
      rabkin@mail.ubc.ca
FAU - Langer, Anatoly
AU  - Langer A
FAU - Ur, Ehud
AU  - Ur E
FAU - Calciu, Cristina-Dana
AU  - Calciu CD
FAU - Leiter, Lawrence A
AU  - Leiter LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130207
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0 (APP protein, human)
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Interleukin-18)
RN  - 0 (Peptide Fragments)
RN  - 0 (Triglycerides)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Amyloid beta-Protein Precursor/*blood
MH  - Biomarkers/*blood
MH  - Blood Pressure/physiology
MH  - C-Reactive Protein/*analysis
MH  - Canada
MH  - Chemokine CCL2/*blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus/*blood
MH  - Diabetes Mellitus, Type 2/blood/complications
MH  - Dyslipidemias/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use
MH  - Hypertension/*blood/drug therapy
MH  - Interleukin-18/*blood
MH  - Male
MH  - Metabolic Syndrome/*blood
MH  - Middle Aged
MH  - Peptide Fragments/*blood
MH  - Risk Assessment
MH  - Triglycerides/blood
MH  - Waist Circumference/physiology
EDAT- 2013/02/08 06:00
MHDA- 2014/01/10 06:00
CRDT- 2013/02/08 06:00
PHST- 2013/02/08 06:00 [entrez]
PHST- 2013/02/08 06:00 [pubmed]
PHST- 2014/01/10 06:00 [medline]
AID - hr2012214 [pii]
AID - 10.1038/hr.2012.214 [doi]
PST - ppublish
SO  - Hypertens Res. 2013 Jun;36(6):550-8. doi: 10.1038/hr.2012.214. Epub 2013 Feb 7.